Correlation Between Pasithea Therapeutics and Rezolute

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Pasithea Therapeutics and Rezolute at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pasithea Therapeutics and Rezolute into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pasithea Therapeutics Corp and Rezolute, you can compare the effects of market volatilities on Pasithea Therapeutics and Rezolute and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pasithea Therapeutics with a short position of Rezolute. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pasithea Therapeutics and Rezolute.

Diversification Opportunities for Pasithea Therapeutics and Rezolute

PasitheaRezoluteDiversified AwayPasitheaRezoluteDiversified Away100%
0.61
  Correlation Coefficient

Poor diversification

The 3 months correlation between Pasithea and Rezolute is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Pasithea Therapeutics Corp and Rezolute in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Rezolute and Pasithea Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pasithea Therapeutics Corp are associated (or correlated) with Rezolute. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Rezolute has no effect on the direction of Pasithea Therapeutics i.e., Pasithea Therapeutics and Rezolute go up and down completely randomly.

Pair Corralation between Pasithea Therapeutics and Rezolute

Given the investment horizon of 90 days Pasithea Therapeutics Corp is expected to under-perform the Rezolute. In addition to that, Pasithea Therapeutics is 1.34 times more volatile than Rezolute. It trades about -0.03 of its total potential returns per unit of risk. Rezolute is currently generating about 0.05 per unit of volatility. If you would invest  195.00  in Rezolute on December 12, 2024 and sell it today you would earn a total of  161.00  from holding Rezolute or generate 82.56% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Pasithea Therapeutics Corp  vs.  Rezolute

 Performance 
JavaScript chart by amCharts 3.21.15Dec2025Feb -60-50-40-30-20-10010
JavaScript chart by amCharts 3.21.15KTTA RZLT
       Timeline  
Pasithea Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Pasithea Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
JavaScript chart by amCharts 3.21.15JanFebMarFebMar11.522.533.5
Rezolute 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Rezolute has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
JavaScript chart by amCharts 3.21.15JanFebMarFebMar3.544.555.5

Pasithea Therapeutics and Rezolute Volatility Contrast

   Predicted Return Density   
JavaScript chart by amCharts 3.21.15-12.62-9.45-6.28-3.12-0.05282.555.237.9110.5913.27 0.0100.0150.0200.025
JavaScript chart by amCharts 3.21.15KTTA RZLT
       Returns  

Pair Trading with Pasithea Therapeutics and Rezolute

The main advantage of trading using opposite Pasithea Therapeutics and Rezolute positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pasithea Therapeutics position performs unexpectedly, Rezolute can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rezolute will offset losses from the drop in Rezolute's long position.
The idea behind Pasithea Therapeutics Corp and Rezolute pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Other Complementary Tools

Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Global Correlations
Find global opportunities by holding instruments from different markets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments